Table 1.
Objective response rates, complete response (CR), and progression‐free interval (PFI) in days for each treatment group among dogs with cutaneous plasmacytosis
| Primary Treatmenta | Number Treated | Number Treated First Line | Overall Response Rate, % | CR, % | PFI (Days) |
|---|---|---|---|---|---|
| Melphalan | 19 | 15 | 74 | 37 | 143 (29–823) |
| Lomustine | 7 | 1 | 71 | 57 | 84 (28–84) |
| Cyclophosphamide | 5 | 0 | 40 | 20 | 46, 70 |
| Combination protocolsb | 3 | 0 | 67 | 67 | 181, 229 |
| Radiation therapy | 3 | 1 | 67 | 33 | 43, 253 |
| Doxorubicin | 2 | 0 | 50 | 0 | 110 |
| Prednisone | 2 | 0 | 0 | 0 | 275 |
| Cannabis oil | 1 | 0 | 100 | 100 | 311 |
| Surgery | 4 | 3 | 100 | 75 | 43, >128, >242, >567 |
a
The majority of dogs treated with melphalan received concurrent prednisone (18 of 19).
b
Combination protocols included 1 dog treated with chlorambucil, cyclophosphamide, and prednisone, and 2 dogs treated with melphalan, lomustine, and cyclophosphamide. All other protocols did not include prednisone.